Develops protein drugs for cancer patients.
Dec 2025Revenue CHF 0.00/yrExpenses CHF 58.1M/yr
No trendCash runway ≈ 1.6 years from Dec 2025
Figures by year
When will Molecular Partners be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was CHF 0.00 and expenses CHF 58.1M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | CHF 0.00 | CHF 58.1M | −CHF 58.1M |
| Dec 2024 | CHF 4.97M | CHF 66.2M | −CHF 61.2M |
| Dec 2023 | CHF 7.04M | CHF 68.1M | −CHF 61.1M |
| Dec 2022 | CHF 190M | CHF 72.9M | CHF 117M |
| Dec 2021 | CHF 9.33M | CHF 72.7M | −CHF 63.4M |
| Dec 2020 | CHF 9.34M | CHF 67.7M | −CHF 58.3M |
| Dec 2019 | CHF 20.4M | CHF 57.0M | −CHF 36.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.